Blog Big Molecule Watch February 04, 2021

Enzene Biosciences Teriparatide Biosimilar Obtains Marketing Authoriation in India

Enzene Biosciences Ltd., located in Pune, India, has announced that it has obtained marketing authorization from the Drug Controller General of India (DCGI) for its first biosimilar product in India. Enzene’s teriparatide biosimilar, indicated for the treatment of osteoporosis, will be marketed through Enzene’s holding company Alkem Laboratories, Ltd.

The post Enzene Biosciences Teriparatide Biosimilar Obtains Marketing Authoriation in India appeared first on Big Molecule Watch.